Our result indicating that only very few patients showed potential breast cancer stem cell markers, CD44+/CD24- (one out of 99 patients) or ALDH1 (four out of 99 patients) may be in accordance with previous studies of proof of concept on cancer stem cells. This evidence concerns the gene ALDH1A1 and breast carcinoma.